Lung cancer Posts - Page 2 of 50 on Medivizor
Navigation Menu

Lung cancer Posts on Medivizor

Evaluating the effectiveness and safety outcomes of durvalumab maintenance after chemoradiotherapy for unresectable stage 3 non-small-cell lung cancer.

Evaluating the effectiveness and safety outcomes of durvalumab maintenance after chemoradiotherapy for unresectable stage 3 non-small-cell lung cancer.

Posted by on Nov 28, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of durvalumab (Imfinzi) maintenance after chemoradiotherapy (CRT) in real-world patients with unresectable stage 3 non-small-cell lung cancer (NSCLC). The data showed that durvalumab maintenance after CRT was safe and showed good short-term survival outcomes in these...

Read More

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Posted by on Nov 7, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...

Read More

Evaluating treatment outcomes of hypofractionated stereotactic radiotherapy in patients with brain metastases.

Evaluating treatment outcomes of hypofractionated stereotactic radiotherapy in patients with brain metastases.

Posted by on Oct 31, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the optimal doses of hypofractionated stereotactic radiation therapy (HSRT) for patients with brain metastases (BM). The data showed that a HSRT dose of 30 Gy or higher delivered in 5 daily fractions was safe and effective in these patients. Some background Stereotactic radiosurgery (SRS) is commonly used in...

Read More

Evaluating the effectiveness of EGFR-TKIs first-line treatment and performance status in older patients with EGFR-mutant NSCLC.

Evaluating the effectiveness of EGFR-TKIs first-line treatment and performance status in older patients with EGFR-mutant NSCLC.

Posted by on Oct 31, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) first-line treatment and performance status in older patients with EGFR-mutant non-small-cell lung cancer (NSCLC). The data showed that older patients with EGFR-mutated NSCLC who received EGFR-TKI first-line treatment with a...

Read More

Evaluating the long-term outcomes of stereotactic ablative radiation therapy and video-assisted thoracic surgery in patients with early-stage non-small cell lung cancer.

Evaluating the long-term outcomes of stereotactic ablative radiation therapy and video-assisted thoracic surgery in patients with early-stage non-small cell lung cancer.

Posted by on Oct 24, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the long-term outcomes of stereotactic ablative radiation therapy (SABR) and video-assisted thoracic surgery (VATS) for the treatment of patients with early-stage non-small cell lung cancer (NSCLC). The data showed that both SABR and VATS led to similar long-term survival outcomes. Some background...

Read More

Evaluating the safety and effectiveness of trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer.

Evaluating the safety and effectiveness of trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer.

Posted by on Oct 24, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of trastuzumab deruxtecan (Enhertu) in patients with previously untreated metastatic HER2-mutant non-small-cell lung cancer (NSCLC). The data showed that trastuzumab deruxtecan was safe and showed strong anticancer activity in these patients. Some background NSCLC is the most common form...

Read More

Comparing the effectiveness and safety of nivolumab plus ipilimumab with chemotherapy versus pembrolizumab plus chemotherapy as first-Line treatment for metastatic NSCLC.

Comparing the effectiveness and safety of nivolumab plus ipilimumab with chemotherapy versus pembrolizumab plus chemotherapy as first-Line treatment for metastatic NSCLC.

Posted by on Oct 17, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of nivolumab (N; Opdivo) plus ipilimumab (I; Yervoy) with chemotherapy versus pembrolizumab (Pem; Keytruda) plus chemotherapy as first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC). The data showed that N-I plus chemotherapy provided similar overall...

Read More

Comparing the effectiveness and safety of single and double immune checkpoint inhibitor-based first-line treatments for advanced non-small cell lung cancer.

Comparing the effectiveness and safety of single and double immune checkpoint inhibitor-based first-line treatments for advanced non-small cell lung cancer.

Posted by on Oct 16, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of single and double immune checkpoint inhibitors (ICI)-based treatments in patients with advanced non-small-cell lung cancer (NSCLC). The data showed that the effectiveness and safety of both single and double ICI-based treatments were similar and higher...

Read More

Evaluating the benefits of radiotherapy after surgery in patients with resectable stage III-N2 non-small cell lung cancer.

Evaluating the benefits of radiotherapy after surgery in patients with resectable stage III-N2 non-small cell lung cancer.

Posted by on Oct 16, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the benefits of postoperative radiotherapy (PORT; radiation after surgery) in patients with resectable stage III-N2 non-small-cell lung cancer (NSCLC). The data showed that PORT significantly increased survival without disease progression and reduced the risk of cancer relapse for these patients. Some background...

Read More

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Posted by on Oct 9, 2021 in Lung cancer | 0 comments

In a nutshell This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT).   Some background Immunotherapy is a type of cancer treatment that makes use of the immune...

Read More

Does tyrosine kinase inhibitors therapy after surgery benefit patients with EGFR-mutant resected NSCLC?

Does tyrosine kinase inhibitors therapy after surgery benefit patients with EGFR-mutant resected NSCLC?

Posted by on Oct 9, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated whether patients with non-small-cell lung cancer (NSCLC) having genetic mutations could benefit from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) therapy after surgery. The data showed that EGFR-TKI therapy after surgery significantly improved survival without disease progression in...

Read More

Is osimertinib an effective treatment for EGFR-mutant advanced non-small cell lung cancer in a real-world practice?

Is osimertinib an effective treatment for EGFR-mutant advanced non-small cell lung cancer in a real-world practice?

Posted by on Oct 3, 2021 in Lung cancer | 0 comments

In a nutshell This study looked at the use of osimertinib (Tagrisso) for the treatment of EGFR-mutant advanced non-small-cell lung cancer (NSCLC) in a real-world practice. It found that osimertinib was confirmed to improve survival without cancer progressing, while the occurrence of blood clots was more common in a real-world...

Read More